A study analyzing the remedies available to target companies in public merger agreements for a buyer's failure to close the transaction because of a breach or financing failure. The study covers all merger agreements entered into in 2011 for debt-financed acquisitions of US, publicly traded companies (excluding REITs) with a deal value of at least $100 million.

The 2012 edition includes new and detailed analysis of the remedy approaches, financing covenants and Xerox provisions seen in 2011.